Physician profile
Bryce C Shutt
NPI 1538128186
$1,035.11
in general payments reported to CMS, 2019-2025
11 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.61 · 2021: $70.38 · 2022: $131 · 2023: $90.71 · 2024: $317 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.83 | 2019-2025 | Lumigan, Alphagan P |
| Dompe US, INC. | $152.71 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $118.68 | 2019-2025 | Argos, Eysuvis, Clareon |
| Biotissue Holdings INC. | $96.83 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $74.53 | 2022-2024 | Vyzulta, Miebo, Xiidra |
| Shire North American Group INC | $58.01 | 2019 | |
| Allergan, INC. | $53.66 | 2021-2022 | |
| Amgen INC. | $23.10 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $21.31 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $19.47 | 2025 | Ryzumvi, Tyrvaya |
| Kala Pharmaceuticals, INC. | $18.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Shutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.